Q4 2017 13F Holders as of 31 Dec 2017
-
Type / Class
-
Equity / Common Stock, par value $0.00001 per share
-
Shares outstanding
-
108M
-
Number of holders
-
99
-
Total 13F shares, excl. options
-
28.5M
-
Shares change
-
-97.8K
-
Total reported value, excl. options
-
$702M
-
Value change
-
-$5.46M
-
Number of buys
-
53
-
Number of sells
-
-51
-
Price
-
$24.66
Significant Holders of Aclaris Therapeutics, Inc. - Common Stock, par value $0.00001 per share (ACRS) as of Q4 2017
123 filings reported holding ACRS - Aclaris Therapeutics, Inc. - Common Stock, par value $0.00001 per share as of Q4 2017.
Aclaris Therapeutics, Inc. - Common Stock, par value $0.00001 per share (ACRS) has 99 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 28.5M shares
of 108M outstanding shares and own 26.29% of the company stock.
Largest 10 shareholders include FMR LLC (2.67M shares), FRANKLIN RESOURCES INC (2.6M shares), DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) (2.23M shares), BlackRock Inc. (2.2M shares), Vivo Capital, LLC (1.65M shares), Sofinnova Management VIII, L.L.C. (1.54M shares), Polar Capital LLP (1.34M shares), Vanguard Group Inc (1.13M shares), D. E. Shaw & Co., Inc. (1.02M shares), and Balyasny Asset Management LLC (928K shares).
This table shows the top 99 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.